Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganetespib + Paclitaxel in Recurrent Ovarian Cancer
NCT01962948Phase 2Terminated
- Sponsor
- Fox Chase Cancer Center
- Start
- Oct 2013
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ganetespib in ovarian epithelial cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (4 arms), sponsored by Fox Chase Cancer Center. Primary endpoints: Recommended Phase II Dose at 28 days, Progression-Free Survival at 6 months and 1 more. Started Oct 2013; status: terminated.
02
Drugs
ganetespib
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT01962948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01962948.